Open label, uncontrolled, pilot, phase II study of histone-deacetylase inhibitor ITF2357 administered orally to subjects aged over 60 years with primary or secondary DLBCL refractory/ relapsed after conventional chemotherapy with or without prior immunotherapy.
Phase of Trial: Phase II
Latest Information Update: 31 May 2011
At a glance
- Drugs Givinostat (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 31 May 2011 New trial record